{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:40:39Z","timestamp":1740184839111,"version":"3.37.3"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.dadr.2024.100261","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T16:50:41Z","timestamp":1721494241000},"page":"100261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Extended-release buprenorphine induction in opioid non-tolerant incarcerated individuals"],"prefix":"10.1016","volume":"12","author":[{"given":"Michael S.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Blue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank J.","family":"Vocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon G.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin R.","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dadr.2024.100261_bib1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","article-title":"Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study","volume":"34","author":"Albayaty","year":"2017","journal-title":"Adv Ther."},{"issue":"12","key":"10.1016\/j.dadr.2024.100261_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/add.15565","article-title":"Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters","volume":"116","author":"Bandara","year":"2021","journal-title":"Addiction"},{"issue":"12","key":"10.1016\/j.dadr.2024.100261_bib3","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/add.15077","article-title":"The association of criminal justice supervision setting with overdose mortality: A longitudinal cohort study","volume":"115","author":"Binswanger","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2024.100261_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.addbeh.2018.02.024","article-title":"Criminal justice continuum for opioid users at risk of overdose","volume":"86","author":"Brinkley-Rubinstein","year":"2018","journal-title":"Addict Behav."},{"key":"10.1016\/j.dadr.2024.100261_bib5","unstructured":"Carson, A.E., Kluckow, R.Correctional population in the United States, 2021 \u2013 Statistical Tables. U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics, February 2023, NCJ 305542."},{"issue":"2","key":"10.1016\/j.dadr.2024.100261_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/08897077.2019.1572052","article-title":"Demystifying buprenorphine misuse: Is afraid of diversion gotten in the way of addressing the opioid crisis?","volume":"40","author":"Doernberg","year":"2019","journal-title":"Subst. Abus"},{"key":"10.1016\/j.dadr.2024.100261_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109254","article-title":"Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder","author":"Evans","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.dadr.2024.100261_bib8","first-page":"126","article-title":"Feasibility of Initiating Treatment with Buprenorphine-Naloxone in a state prison for opiate dependent inmates nearing release","volume":"1","author":"Garcia","year":"2007","journal-title":"American Journal on Addictions"},{"key":"10.1016\/j.dadr.2024.100261_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102768","article-title":"A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System","volume":"81","author":"Grella","year":"2020","journal-title":"Int J Drug Policy."},{"key":"10.1016\/j.dadr.2024.100261_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.drugalcdep.2014.05.011","article-title":"A randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entry","volume":"142","author":"Gordon","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.dadr.2024.100261_bib11","article-title":"A comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail","volume":"Sept. 128","author":"Gordon","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2024.100261_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jsat.2017.04.008","article-title":"Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder","volume":"78","author":"Haasen","year":"2017","journal-title":"J Subst Abuse Treat."},{"key":"10.1016\/j.dadr.2024.100261_bib13","article-title":"Non-fatal drug overdose after release from prison: A prospective data linkage study","volume":"206","author":"Keen","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"12","key":"10.1016\/j.dadr.2024.100261_bib14","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1377\/hlthaff.2017.0890","article-title":"Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine","volume":"36","author":"Krawczyk","year":"2017","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"10.1016\/j.dadr.2024.100261_bib15","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.dadr.2024.100261_bib16","article-title":"Medication-assisted treatment for opioid use disorder in jails and prisons: A planning and implementation toolkit","author":"Mace","year":"2020","journal-title":"Natl. Counc. Behav. Health Vital.-. Strateg."},{"key":"10.1016\/j.dadr.2024.100261_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107858","article-title":"Estimating the impact of wide scale uptake of screening and medications for opioid use disorder in US prisons and jails","volume":"208","author":"Macmadu","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"12","key":"10.1016\/j.dadr.2024.100261_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003002","article-title":"Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review","volume":"16","author":"Malta","year":"2019","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.dadr.2024.100261_bib19","first-page":"472","article-title":"Prescribing Opioid Replacement Therapy in U.S. Correctional Settings","volume":"45","author":"Modesto-Lowe","year":"2017","journal-title":"J Am Acad Psychiatry Law."},{"key":"10.1016\/j.dadr.2024.100261_bib20","article-title":"Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation","volume":"161","author":"Pourtaher","year":"2024","journal-title":"J. Subst. Use Addict. Treat."},{"issue":"1","key":"10.1016\/j.dadr.2024.100261_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s40352-022-00174-w","article-title":"Buprenorphine\/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation","volume":"10","author":"Regenstreif","year":"2022","journal-title":"Health Justice"},{"issue":"4","key":"10.1016\/j.dadr.2024.100261_bib22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s11524-010-9438-4","article-title":"Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment","volume":"87","author":"Springer","year":"2010","journal-title":"J Urban Health."},{"issue":"12","key":"10.1016\/j.dadr.2024.100261_bib23","doi-asserted-by":"crossref","first-page":"e2138807","DOI":"10.1001\/jamanetworkopen.2021.38807","article-title":"Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021","volume":"4","author":"Thakrar","year":"2021","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.dadr.2024.100261_bib24","unstructured":"U.S. Department of Justice. (2022, April 55). Justice Department Issues Guidance on Protections for People with Opioid Use Disorder under the Americans with Disabilities Act [Press release]. \u3008https:\/\/www.justice.gov\/opa\/pr\/justice-department-issues-guidance-protections-people-opioid-use-disorder-under-americans\u3009."},{"issue":"9","key":"10.1016\/j.dadr.2024.100261_bib25","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","article-title":"Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial","volume":"74","author":"Walsh","year":"2017","journal-title":"JAMA Psychiatry"}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724624000453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724624000453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:10:03Z","timestamp":1726704603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724624000453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":25,"alternative-id":["S2772724624000453"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2024.100261","relation":{},"ISSN":["2772-7246"],"issn-type":[{"type":"print","value":"2772-7246"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended-release buprenorphine induction in opioid non-tolerant incarcerated individuals","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2024.100261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100261"}}